73 results
6-K
EX-99.1
GLPG
Galapagos NV
3 May 24
Galapagos reports first quarter 2024 financial results
9:30am
forward with a renewed focus, a differentiated and expanding R&D pipeline, and competitive technology platforms to bring innovation to patients around
6-K
EX-99.5
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
deductible from future taxable profits
Other deferred taxes representing assets
Investment deduction
Deduction for innovation income
Excess depreciations
DBI
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
regarding the timing and likelihood of business development projects and external innovation, statements regarding the amount and timing of potential future … -changing science and innovation for more years of life and quality of life. Our Mission We accelerate transformational innovation through the relentless
6-K
EX-99.15
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
science and innovation to deliver more years of life and quality of life. We are committed to improving patients’ lives worldwide by targeting … and oncology with the aim to transform patient outcomes through life-changing science and innovation. Galapagos is at a pivotal juncture resetting its
6-K
EX-99.1
GLPG
Galapagos NV
29 Mar 24
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
6:14am
and accelerating innovation to address important medical needs.”
About Galapagos
We are a biotechnology company with operations in Europe and the US
6-K
EX-99.1
dr08699i
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
6-K
EX-99.1
a913p
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
6-K
EX-99.1
bttzg kf26bmo
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
6-K
EX-99.1
bgjkc0y
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
EX-99.1
nesu5 l5fcz3kde4
20 Sep 23
Galapagos appoints Simon Sturge to its Board of Directors
6:00am
6-K
EX-99.1
5uaq 6v802
30 Aug 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
6:31am
6-K
EX-99.2
96wgxpm5wkrwkr5l 2y
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
7ase5cm
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
hpgafw3s
15 Jun 23
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
5:03pm
6-K
EX-99.1
xcrup95i96j20v
13 Jun 23
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
7:53am
6-K
EX-99.1
2q0xnodpy3 de9r
12 Jun 23
Current report (foreign)
7:32am
6-K
EX-99.1
g145qo0 gbxakxpdh3
25 May 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis
5:49pm
6-K
EX-99.1
ugpxb9g 3iom9b6mj36c
23 May 23
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
7:30am
6-K
EX-99.1
ceuqmam
31 Mar 23
Current report (foreign)
6:05am